Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | CDK4 | P11802 | 19/20 | 0.53 |
| ▸ | CCND1 | P24385 | 19/20 | 0.53 |
| ▸ | CCND2 | P30279 | 15/20 | 0.53 |
| ▸ | CCND3 | P30281 | 15/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.53 |
| ▸ | CDK2 | P24941 | 10/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188921 | 0.90 | MAPK1 (0.58) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL189169 | 0.90 | KDM4E (0.58) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL190014 | 0.90 | KDM4E (0.58) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL14306582 | 0.85 | CDK4 (0.61) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL3338688 | 0.84 | CDK4 (0.56) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL188366 | 0.84 | MAPK1 (0.52) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL4355205 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL3338980 | 0.83 | CDK4 (0.73) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL14300938 | 0.83 | PIK3CD (0.58) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL14306579 | 0.83 | CDK4 (0.46) | CDK4CCND1CCND2CCND3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | claimed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | claimed |
| EP-1931670-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | Exelixis, Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2007044698-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2007044698-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | KDM4E 761/4885ALDH1A1 4075/4885GLA 3428/4885 |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | PIK3CA, PIK3CD, PIK3CB | KDM4E 2571/4885ALDH1A1 1878/4885GLA 3184/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | KDM4E 761/4885ALDH1A1 4075/4885GLA 3428/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | KDM4E 729/4885ALDH1A1 4089/4885GLA 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.